Apotex Health (APTX) investor relations material

Executive summary

• Achieved a strong start to fiscal 2027, with Q1 results slightly above expectations, driven by 2% revenue growth (ex-VLLP), robust Canadian performance, and continued execution of the Journey of Health strategy.

• Completed an upsized $1.5 billion IPO, applying $800 million to debt reduction and strengthening the balance sheet.

• Advanced key product launches, including first-to-market semaglutide in Canada, sitagliptin and INFUVITE in the U.S., and expanded the U.S. branded portfolio with the Cumberland acquisition.

• Productivity initiatives targeting over $100 million in annual savings for fiscal 2027 are on track.

• Introduced fiscal 2027 guidance with upper mid-single-digit revenue growth (ex-VLLP) and adjusted EBITDA margin of ~30%.

Financial highlights

• Q1 revenue was $848 million, up 2% year-over-year excluding VLLP, with 11% growth in Canada and new launches driving performance.

• Adjusted EBITDA (ex-VLLP) was $259 million (30.6% margin), flat year-over-year; net loss of $38 million due to IPO-related share-based compensation and FX losses.

• Adjusted net income (ex-VLLP) was $142 million, down 19% year-over-year, reflecting prior year exclusive launch dynamics.

• Gross profit (ex-VLLP) was $421 million, with a gross margin of 49.7%, down 240 bps year-over-year.

• Operating free cash flow (ex-VLLP) was $142 million, up $56 million year-over-year.

Outlook and guidance

• Fiscal 2027 guidance targets upper mid-single-digit revenue growth (ex-VLLP) and adjusted EBITDA margin around 30%.

• Double-digit revenue growth expected in H2, with launch pipeline projected to contribute ~10% of total revenue, including a 180-day exclusive U.S. product.

• Productivity initiatives are expected to deliver over $100 million in annual savings.

• Margin variability anticipated due to launch timing and competition, but overall margins to remain in a tight band.